Key Details
Annual ROE
-37.09%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 29, 2023Recent annual earnings:
Mar 29, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with AKUS included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Akouos doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Akouos?
- What is the ticker symbol for Akouos?
- Does Akouos pay dividends?
- What sector is Akouos in?
- What industry is Akouos in?
- What country is Akouos based in?
- When did Akouos go public?
- Is Akouos in the S&P 500?
- Is Akouos in the NASDAQ 100?
- Is Akouos in the Dow Jones?
- When was Akouos's last earnings report?
- When does Akouos report earnings?
What is the primary business of Akouos?
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
What is the ticker symbol for Akouos?
The ticker symbol for Akouos is NASDAQ:AKUS
Does Akouos pay dividends?
No, Akouos does not pay dividends
What sector is Akouos in?
Akouos is in the Healthcare sector
What industry is Akouos in?
Akouos is in the Biotechnology industry
What country is Akouos based in?
Akouos is headquartered in United States
When did Akouos go public?
Akouos's initial public offering (IPO) was on 26 June 2020
Is Akouos in the S&P 500?
No, Akouos is not included in the S&P 500 index
Is Akouos in the NASDAQ 100?
No, Akouos is not included in the NASDAQ 100 index
Is Akouos in the Dow Jones?
No, Akouos is not included in the Dow Jones index
When was Akouos's last earnings report?
Akouos's most recent earnings report was on 29 March 2023
When does Akouos report earnings?
The date for Akouos's next earnings report has not been announced yet